Diuretic Activity (diuretic + activity)

Distribution by Scientific Domains


Selected Abstracts


Structure of Cymbidine A, a Monomeric Peptidoglycan-Related Compound with Hypotensive and Diuretic Activities, Isolated from a Higher Plant, Cymbidium goeringii (Orchidaceae).

CHEMINFORM, Issue 44 2007
Kinzo Watanabe
Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF. [source]


Enhancement in the absorption of water and electrolytes from rat intestine by Hemidesmus indicus R. Br. root (water extract)

PHYTOTHERAPY RESEARCH, Issue 7 2004
D. A. Evans
Abstract Hemidesmus indicus root in the form of suspension in water (10 mg/ml) containing 15.5 mM NaCl, 3 mM KCl and 12 mM glucose, when injected into the ligated jejunal sac (1 ml/sac) of rat, increased the absorption of water, Na+ and K+ (but not glucose) from the sac. This bioactivity was present in the water extract (5 or 10 mg/sac) of the root and not in the hexane extract. In contrast, the ethanol extract decreased the absorption of water and electrolytes from the jejunal sac. The effect of water extract was not affected by heat at 100 °C for 30 min. Intraperitoneal administration of the water extract (50 to 200 mg/kg) was devoid of any signi,cant effect on the jejunal absorption. Neither the root suspension nor the water extract (125,500 mg/kg) showed any signi,cant anti-ulcer and diuretic activities in rats. The intestinal motility was also not in,uenced by the root (water extract) when tested in mice. The present study indicates that H. indicus root powder or its water extract can be incorporated in oral rehydrating salt solution (ORS) for increasing its anti-diarrhoeal ef,cacy. Copyright © 2004 John Wiley & Sons, Ltd. [source]


Cloning and transcriptional expression of a leucokinin-like peptide receptor from the Southern cattle tick, Boophilus microplus (Acari: Ixodidae)

INSECT MOLECULAR BIOLOGY, Issue 5 2000
S. P. Holmes
Abstract Leucokinins are invertebrate neuropeptides that exhibit myotropic and diuretic activity. Only one leucokinin-like peptide receptor is known, the lymnokinin receptor from the mollusc Lymnaeastagnalis. A cDNA encoding a leucokinin-like peptide receptor was cloned from the Southern cattle tick, Boophilus microplus, a pest of cattle world-wide. This is the first neuropeptide receptor known from the Acari and the second known in the subfamily of leucokinin-like peptide G-protein-coupled receptors. The deduced amino acid sequence exhibits 40% identity to the lymnokinin receptor. The receptor transcript is present in all tick life stages as determined by semiquantitative reverse transcription polymerase chain reaction. We also propose that the sequence AAF50775.1 from the Drosophila melanogaster genome (CG10626) encodes the first identified insect leucokinin receptor. [source]


Quantitative HPLC method and pharmacokinetic studies of ergosta-4,6,8(14),22-tetraen-3-one, a natural product with diuretic activity from Polyporus umbellatus

BIOMEDICAL CHROMATOGRAPHY, Issue 10 2010
Ying-Yong Zhao
Abstract A simple and specific HPLC method with dual wavelength UV detection for the determination of ergosta-4,6,8(14),22-tetraen-3-one (ergone) in rat plasma was developed and proved to be efficient. The method used ergosterol as internal standard (IS). Following a single-step protein precipitation, the analyte and IS were separated on an Inertsil ODS-3 column with a mobile phase containing methanol,water (99:1, v/v) at a flow rate of 1,mL/min. The analytes were detected by using UV detection at wavelength of 350 (ergone) and 283 (IS) nm, respectively. The calibration curve was linear over the range of 0.1,2.0,µg/mL and the lower limit of quantification was 0.1,µg/mL. The intra-day and inter-day precision studies showed good reproducibility with RSD less than 8.5%. The intra-day and inter-day accuracy ranged from 95.6 to 104%. Mean extraction recovery was above 95% at the low, medium and high concentrations. The present HPLC-UV method was simple and reliable. The method described herein had been successfully applied for the pharmacokinetic studies in male SD rats after administration of 20,mg/kg dose of solution of ergone. Copyright © 2010 John Wiley & Sons, Ltd. [source]


Pharmacological Profile and Therapeutic Potential of BM-573, a Combined Thromboxane Receptor Antagonist and Synthase Inhibitor

CARDIOVASCULAR THERAPEUTICS, Issue 1 2005
Alexandre Ghuysen
ABSTRACT BM-573 (N-terbutyl-N,-[2-(4,-methylphenylamino)-5-nitro-benzenesulfonyl]urea), a torsemide derivative, is a novel non-carboxylic dual TXA2 synthase inhibitor and receptor antagonist. The pharmacological profile of the drug is characterized by a higher affinity for the thromboxane receptor than that of SQ-29548, one of the most powerful antagonists described to date, by a complete prevention of human platelet aggregation induced by arachidonic acid at a lower dose than either torsemide or sulotroban, and by a significantly prolonged closure time measured by the platelet function analyser (PFA-100®). Moreover, at the concentrations of 1 and 10 ,M, BM-573 completely prevented production of TXB2 by human platelets activated by 0.6 mM of arachidonic acid. BM-573 prevents rat fundus contraction induced by U-46619 but not by prostacyclin or other prostaglandins. Despite possessing a chemical structure very similar to that of a diuretic torsemide, BM-573 has no diuretic activity. BM-573 does not prolong bleeding time and, unlike some of the other sulfonylureas, has no effect on blood glucose levels. In vivo, BM-573 appears to have antiplatelet and antithrombotic activities since it reduced thrombus weight and prolonged the time to abdominal aorta occlusion induced by ferric chloride. BM-573 also relaxed rat aorta and guinea pig trachea precontracted with U-46619. In pigs, BM-573 completely antagonized pulmonary hypertensive effects of U-46619 and reduced the early phase of pulmonary hypertension in models of endotoxic shock and pulmonary embolism. Finally, BM-573 protected pigs from myocardial infarction induced by coronary thrombosis. These results suggest that BM-573 should be viewed as a promising therapeutic agent in the treatment of pulmonary hypertension and syndromes associated with platelet activation. [source]